21:57 , Jun 14, 2019 |  BC Extra  |  Preclinical News

June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells   The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in...
14:19 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

MAT2A identified as a target in solid and liquid cancers

DISEASE CATEGORY: Cancer INDICATION: Lung; leukemia; lymphoma; solid tumors Cell and mouse studies suggest inhibiting MAT2A could help treat lung and other solid and liquid cancers. In a panel of human cancer cell lines, including...
23:05 , May 2, 2019 |  BC Innovations  |  Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 1Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
18:47 , Apr 24, 2019 |  BC Extra  |  Financial News

Hong Kong firms to invest in Singapore biotechs with $200M fund

Aptorum Group and Aeneas Capital said Wednesday they are launching a $200 million healthcare and life science fund that could be used to invest in Singapore biotech start-ups. The companies said they also plan to...
00:52 , Jan 23, 2019 |  BC Extra  |  Company News

Management tracks: GSK, A*STAR, Moderna

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Philip Hampton will step down as chairman ahead of the pharma’s planned split of its consumer healthcare and innovative R&D businesses. The pharma said it has started to search for...
21:46 , Jan 17, 2019 |  BC Innovations  |  Finance

Public funding highlights

Public funding highlights Selected developments and initiatives in 4Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
20:22 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting KDM4B alone or in combination with PI3K could help treat PTEN-deficient triple-negative breast cancer (TNBC). In a PTEN-deficient TNBC cell line, two siRNAs against KDM4B...
22:19 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Public funding highlights: 3Q18

Public funding highlights: 3Q18 Selected developments and initiatives in 3Q18 from major sources of public funding including NIH , the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes of Health...
16:15 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; breast cancer; ovarian cancer Cell culture and mouse studies suggest niclosamide could help treat p53-mutant colorectal, ovarian and breast cancers. High throughput screening of a library of 1,600 approved compounds in p53-wild...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...